Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial

被引：3
|
作者：
Nakamura, Ryosuke [1 ]
Hirata, Takero [1 ]
Suzuki, Osamu [1 ]
Otani, Keisuke [1 ]
Kai, Naoki [1 ]
Hatano, Koji [2 ]
Fujita, Kazutoshi [2 ]
Uemura, Motohide [2 ]
Imamura, Ryoichi [2 ]
Tanaka, Kazunori [1 ]
Yoshioka, Yasuo [3 ]
Nonomura, Norio [2 ]
Ogawa, Kazuhiko [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Urol, Osaka, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Radiat Oncol, Tokyo, Japan
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 04期
关键词：
SBRT; CyberKnife; prostate cancer; INTENSITY-MODULATED RADIOTHERAPY; FRACTIONATION; BRACHYTHERAPY;
D O I：
10.21873/anticanres.14162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The present study aimed to evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for localized prostate cancer. Patients and Methods: We investigated 25 patients treated with SBRT of 35 Gy per five fractions from May 2014 to March 2015. Results: The median age of patients was 70 years, four (16%) patients were low risk and 21 (84%) were intermediate risk. Seven (28%) patients received neoadjuvant androgen-deprivation therapy. The median follow-up time was 53 months. Grade 2 acute and late genitourinary toxicities were observed in five (20%) and two (8%) patients and there were no Grade 2 gastrointestinal toxicities. There were no Grade 3 or higher acute or late toxicities at 2 years follow-up. The biochemical relapse-free survival rate at 2 years was 100%. Conclusion: SBRT of 35 Gy per five fractions is a promising treatment method in the short term for prostate cancer.
引用
收藏
页码：2053 / 2057
页数：5
相关论文
共 50 条
  • [21] Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancer
    Boyer, Matthew J.
    Papagikos, Michael A.
    Kiteley, Rex
    Vujaskovic, Zeljko
    Wu, Jackie
    Lee, W. Robert
    RADIATION ONCOLOGY, 2017, 12
  • [22] Long-term Outcomes of Stereotactic Body Radiotherapy for Low-Risk and Intermediate-Risk Prostate Cancer
    Kishan, Amar U.
    Dang, Audrey
    Katz, Alan J.
    Mantz, Constantine A.
    Collins, Sean P.
    Aghdam, Nima
    Chu, Fang-I
    Kaplan, Irving D.
    Appelbaum, Limor
    Fuller, Donald B.
    Meier, Robert M.
    Loblaw, D. Andrew
    Cheung, Patrick
    Pham, Huong T.
    Shaverdian, Narek
    Jiang, Naomi
    Yuan, Ye
    Bagshaw, Hilary
    Prionas, Nicolas
    Buyyounouski, Mark K.
    Spratt, Daniel E.
    Linson, Patrick W.
    Hong, Robert L.
    Nickols, Nicholas G.
    Steinberg, Michael L.
    Kupelian, Patrick A.
    King, Christopher R.
    JAMA NETWORK OPEN, 2019, 2 (02)
  • [23] Management of low- and intermediate-risk prostate cancer
    Henk van der Poel
    Laurence Klotz
    Christian G. Stief
    World Journal of Urology, 2015, 33 : 905 - 906
  • [24] Management of low- and intermediate-risk prostate cancer
    van der Poel, Henk
    Klotz, Laurence
    Stief, Christian G.
    WORLD JOURNAL OF UROLOGY, 2015, 33 (07) : 905 - 906
  • [25] Radiotherapy in low and intermediate-risk prostate cancer
    Yalman, Deniz
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2013, 12 (02): : 86 - 91
  • [26] A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
    Kawakami, S.
    Tsumura, H.
    Satoh, T.
    Tabata, K.
    Sekiguchi, A.
    Kainuma, T.
    Nakano, M.
    Iwamura, M.
    Ishiyama, H.
    RADIATION ONCOLOGY, 2022, 17 (01)
  • [27] Five-Year Outcomes From a Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
    Meier, R.
    Beckman, A.
    Henning, G.
    Mohideen, N.
    Woodhouse, S. A.
    Cotrutz, C.
    Kaplan, I. D.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S33 - S34
  • [28] A phase II trial of stereotactic body radiotherapy in 4 fractions for patients with localized prostate cancer
    S. Kawakami
    H. Tsumura
    T. Satoh
    K. Tabata
    A. Sekiguchi
    T. Kainuma
    M. Nakano
    M. Iwamura
    H. Ishiyama
    Radiation Oncology, 17
  • [29] Assessment of Pretreatment Diffusion Parameters in Low- and Intermediate-Risk Prostate Cancer Patients Treated with Stereotactic Ablative Radiotherapy
    Kedves, A.
    Kisivan, K.
    Glavak, C.
    Lorincz, A.
    Kovacs, A.
    Lakosi, F.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (SUPPL 1) : S113 - S113
  • [30] Stereotactic body radiotherapy with a focal boost to the MRI-visible tumor as monotherapy for low- and intermediate-risk prostate cancer: early results
    Aluwini, Shafak
    van Rooij, Peter
    Hoogeman, Mischa
    Kirkels, Wim
    Kolkman-Deurloo, Inger-Karine
    Bangma, Chris
    RADIATION ONCOLOGY, 2013, 8
12345